Internal Medicine, Hematology & Oncology · Van Nuys, CA
NPI
1508885088
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
15211 Vanowen St Ste 201
Van Nuys, CA, 91405
Phone (818) 574-3798
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.5M
73,426 services
Medicare patients, 2024
507
Average age 73
Drug cost, 2024
$6.0M
1,739 prescriptions
Company payments, 2025
$6,508
From 51 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nubar Boghossian was code J0897 (injection, denosumab, 1 mg), 5,839 times for 46 patients. In total Nubar Boghossian billed 73,426 services in 87 codes, and Medicare paid $1.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-09-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 5,839 | 46 | $20.54 | $120K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,602 | 48 | $0.09 | $234 |
| 99214 Office E&M - Established | Office | 974 | 363 | $99.85 | $97K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 771 | 11 | $0.08 | $58.11 |
| 96372 Injection Administration | Office | 595 | 109 | $11.67 | $6,946 |
| 99213 Office E&M - Established | Office | 564 | 286 | $69.94 | $39K |
| 96127 Behavioral Health Services | Office | 447 | 288 | $3.30 | $1,476 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 371 | 12 | $0.72 | $266 |
| 36415 Venipuncture Blood Collection | Office | 347 | 129 | $8.61 | $2,988 |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 280 | 42 | $0.92 | $256 |
| 96366 Intravenous Infusion, Hydration | Office | 275 | 13 | $17.82 | $4,901 |
| 96367 Intravenous Infusion, Hydration | Office | 200 | 47 | $23.79 | $4,758 |
| 96365 Intravenous Infusion, Hydration | Office | 194 | 35 | $54.49 | $11K |
| 96413 Chemotherapy Administration | Office | 189 | 31 | $112.03 | $21K |
| J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 182 | 17 | $1.03 | $188 |
By year: 2022 $340K for 42,324 services; 2023 $741K for 58,819 services; 2024 $1.5M for 73,426 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 347 | 129 | $8.61 | $2,988 |
| 85025 Blood Count | 119 | 32 | $7.56 | $900 |
Medicare prescription drug claims, 2024
In 2024, the drug Nubar Boghossian prescribed most often to Medicare patients was Letrozole, with 244 prescriptions and refills. In total Nubar Boghossian wrote 1,739 Medicare prescriptions that cost $6.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 244 | 432 | 81 | $3,047 |
| Procrit Epoetin Alfa | 74 | 74 | 24 | $233K |
| Palonosetron Hcl Generic | 60 | 60 | Under 11 | $2,011 |
| Anastrozole Generic | 51 | 89 | 19 | $400 |
| Dexamethasone Generic | 48 | 55 | 18 | $526 |
| Lupron Depot Leuprolide Acetate | 45 | 72 | Under 11 | $147K |
| Dexamethasone Sodium Phosphate Generic | 44 | 44 | Under 11 | $252 |
| Diphenhydramine Hcl Generic | 44 | 44 | Under 11 | $84.05 |
| Verzenio Abemaciclib | 43 | 43 | Under 11 | $601K |
| Carboplatin Generic | 37 | 37 | Under 11 | $2,015 |
| Famotidine Famotidine/Pf | 37 | 37 | Under 11 | $52.15 |
| Retacrit Epoetin Alfa-Epbx | 36 | 36 | Under 11 | $31K |
| Zarxio Filgrastim-Sndz | 35 | 35 | 13 | $32K |
| Imbruvica Ibrutinib | 31 | 32 | Under 11 | $566K |
| Exemestane Generic | 30 | 53 | 16 | $5,295 |
Brand drugs: 719 claims; generic drugs: 1,020 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nubar Boghossian $6,508 ($6,508 in general payments such as food, travel and fees) from 51 companies. The largest payer was Pfizer Inc. with $551.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 24 | $551 |
| AstraZeneca Pharmaceuticals LP AZN | 17 | $478 |
| Abbvie Inc. ABBV | 9 | $408 |
| Gilead Sciences, Inc. GILD | 9 | $247 |
| GlaxoSmithKline, LLC. GSK | 5 | $238 |
| Janssen Biotech, Inc. JNJ | 9 | $233 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 8 | $218 |
| E.R. Squibb & Sons, L.L.C. BMY | 10 | $216 |
| Sobi, Inc SOBI.ST | 9 | $215 |
| Merck Sharp & Dohme LLC MRK | 7 | $214 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.